Tag Archive for: plaque psoriasis

The regulator added atopic dermatitis to the label of Arcutis Biotherapeutics’ topical PDE4 inhibitor Zoryve for the treatment of patients six years of age and older.

Carlos Dortrait, senior vice president & general manager of U.S. Immunology & Neuroscience at Bristol Myers Squibb, explains the importance of empowering patients and giving them the confidence to speak with doctors so they can seek the treatment they need, in this case for treating plaque psoriasis. Actress, writer, and producer Mindy Kaling recently joined actor Ted Danson in the BMS “SO, Have You Found It?” campaign (with their video slated to be released soon), which aims to strengthen the voices of U.S. patients living with the condition. Danson has been living with plaque psoriasis for many years and Kaling, who does not have psoriasis, has the role of patient empowerment through self advocacy.

Like its branded reference product, Selarsdi is a subcutaneous injection that can be used to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in pediatric and adult patients. Unlike Stelara, however, Selarsdi is not approved for Crohn’s disease and ulcerative colitis.

The initiative spotlights the resilience of around two million Americans with moderate to severe plaque psoriasis, aiming to amplify their voices, underscoring the strength of their inner vibe, the “it” factor that makes someone uniquely them. The campaign signifies a shift in dialogue from the challenges associated with the condition to empowering individuals to confidently navigate their plaque psoriasis in partnership with their dermatologists.

Johnson & Johnson’s Protagonist-partnered oral psoriasis candidate was able to sustain its therapeutic benefit through one year, according to data presented on Saturday at the American Academy of Dermatology annual meeting.

Fresh off its $259 million Series C funding round, Alumis unveiled mid-stage data Saturday for its TYK2 inhibitor ESK-001 demonstrating strong symptomatic improvement in moderate-to-severe plaque psoriasis.

The FDA on Friday approved Alvotech and Teva’s Simlandi (adalimumab-ryvk), a biosimilar to AbbVie’s blockbuster antibody therapy Humira (adalimumab), ending a long and difficult regulatory road for the partners.

The agency approved the drug to treat multiple inflammatory diseases.

Following a delay and an initial rejection, UCB’s IL-17A/IL-17F blocker bimekizumab was approved for moderate-to-severe plaque psoriasis, which will now be marketed with the brand name Bimzelx.

Nearly two million people are living with moderate to severe plaque psoriasis in the U.S., but patients often face stigma and feel misunderstood by those around them.